We then analysed the expression of activated (phosphorylated) Akt and MAPK in primary tumours and corresponding metastatic sites with an already known EGFR status, with the aim to define better the EGFR-related molecular profile of colorectal cancer, to serve as a tool for treatment selection. This evidence concerns the gene AKT1 and colorectal cancer.